Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

Stock Information for Viracta Therapeutics Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Viracta Therapeutics Inc Com

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma
Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of SNSS, LOAC, FBSS, and CPAH Mergers
ALERT: Halper Sadeh LLP Investigates TDY, TCP, BEAT, HCAP, SNSS; Shareholders Are Encouraged to Contact the Firm
SHAREHOLDER ALERT: WeissLaw LLP Reminds HLIX, XLNX, SNSS, and AKER Shareholders About Its Ongoing Investigations
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers - PNM, TNAV, SNSS, ZAGG, ELY
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of UROV, SNSS, TCF, and PS Mergers
SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.